FDA Reopens Comment Period on Notice of Possible Revisions to Guidances for Industry Scale-Up and Postapproval Changes

FDA reopened the comment period for an additional 30 days for the docket to solicit public comment on the multiple guidances for industry on scale-up and postapproval changes (SUPAC) for specific dosage forms